In conclusion, HDAC inhibitor ITF2357 may inhibit Rad51 and reduce the resistance of mut-KRAS NSCLC to Pem by inhibiting HDAC2 and upregulating miR-130a-3p. The gene discussed is HDAC9; the disease is non-small cell lung carcinoma.